Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata

    October 2022 in “ Dermatologic Therapy
    Yuqian Wang, Taoming Liu, Sheng Li, Sha Tang, Pei-Yi Lin, Yu Ding, Qingguo Sun, Dexi Zhu, Jianjun Qiao, Hong Fang
    Image of study
    TLDR Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
    The study "Efficacy and safety of baricitinib in patients with refractory alopecia areata" conducted by Yuqian Wang and colleagues involved 11 patients with refractory alopecia areata (AA) who were treated with baricitinib. All patients had previously received at least one therapy for more than a year, including minoxidil, steroids, phototherapy, acupuncture, or herbal medicine, but the response was poor. After 20 weeks of treatment with baricitinib, 2 patients (18%) achieved complete hair regrowth, 6 patients (55%) had partial hair regrowth, and 3 patients (27%) had no hair regrowth. Adverse events were mild and included nausea, folliculitis, and mild increases in liver transaminase levels. The study concluded that baricitinib is efficacious in treating refractory AA, but further trials are needed to confirm its safety and efficacy.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    6 / results

    Related

    3 / results
      Linear Alopecia Areata

      research Linear Alopecia Areata

      4 citations ,   November 2018 in “JAAD case reports”
      Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

      research Treating Resistant Cases of Alopecia Universalis

        May 2018 in “Journal of cosmetology & trichology”
      Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.